z-logo
Premium
Usefulness of a modified inflammation‐based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma
Author(s) -
Ishizuka Mitsuru,
Kubota Keiichi,
Kita Junji,
Shimoda Mitsugi,
Kato Masato,
Sawada Tokihiko
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21857
Subject(s) - medicine , hepatocellular carcinoma , hypoalbuminemia , univariate analysis , gastroenterology , surgery , multivariate analysis
Objective To assess and compare the predictive values of the hepatic Glasgow Prognostic Score (hGPS) and Cancer of the Liver Italian Program (CLIP) score in patients undergoing surgery for primary hepatocellular carcinoma (HCC). Methods The hGPS was calculated as follows: patients with an elevated level of C‐reactive protein (CRP) (>0.3 mg/dl) were allocated a hGPS of 1 or 2 depending on the absence or presence of hypoalbuminemia (<3.5 g/dl), and patients without an elevation of the CRP level (≤0.3 mg/dl) were allocated a hGPS of 0. Results Three hundred patients were evaluated. The hGPS divided patients into three independent groups, and that a hGPS of 2 predicted a higher mortality rate ( P  < 0.001) than a hGPS of 0 or 1. Univariate analysis demonstrated that hGPS (0, 1/2) ( P  = 0.010) was one of the factors predictive of postoperative mortality, along with the CLIP score (0, 1/≥2) ( P  = 0.021). Comparative analysis using these two factors showed that the hGPS was predictively superior to the CLIP score ( P  = 0.033). Conclusions The hGPS is able to divide patients undergoing surgery for primary HCC into three independent groups, and is considered to be an important factor predictive of postoperative mortality in such patients. J. Surg. Oncol. 2011;103:801–806. © 2011 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here